sarepta therapeutics nasdaq - Search News

News

FDA to Ask Sarepta to Halt Elevidys Shipments

Seeking Alpha on MSN · 15h

Sarepta to continue Elevidys shipments despite FDA request to halt

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after patient deaths. Read more here.

The Wall Street Journal · 1d

Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to the death of a 51-year-old man last month who received the treatment in a clinical trial.

Insider Monkey on MSN · 4d

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, Sarepta Therapeutics started facing a temporary suspension of shipments for ELEVIDYS,

2d

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

3d

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

InvestorsHub on MSN1d

Sarepta Shares Sink After Patient Death in Early-Stage Gene Therapy Trial

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

1don MSN

Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta ...

3don MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

1d

Sarepta Therapeutics Provides Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results